Enzalutamide D6

Enzalutamide D6 is a deuterated derivative of Enzalutamide, a non-steroidal antiandrogen drug. Enzalutamide D6 is used in the treatment of metastatic castration-resistant prostate cancer (mCRPC) in men who have received prior chemotherapy. It works by blocking the binding of androgens (male hormones) to the androgen receptor, which slows the growth and spread of prostate cancer cells. Enzalutamide D6 is an isotopically labeled compound, meaning that six deuterium atoms have been substituted for six hydrogen atoms in the molecular structure. This labeling allows for easy tracking and analysis of the compound in biological systems. It has a molecular formula of C21H16D6F4N4O2 and a molecular weight of 446.51 g/mol. The recommended dosage of Enzalutamide D6 is 160 mg taken orally once daily. It is important to follow the prescribed dosage and administration instructions carefully, as overdose or improper use can lead to unwanted side effects such as fatigue, headache, nausea, and high blood pressure. Enzalutamide D6 is metabolized primarily by the liver and excreted in the feces. It has a half-life of approximately 5-8 days, meaning that it takes this amount of time for half of the drug to be eliminated from the body. Enzalutamide D6 has been extensively studied in clinical trials and has shown promising results in the treatment of mCRPC, offering improved survival rates and quality of life for patients.